BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC
Moreover, although PET-based fluorescence switching enables effective off-on activation, the extent of initial quenching and the magnitude of signal recovery upon activation are highly dependent on the COFs electronic structure and local microenvironment, necessitating precise molecular engineering to balance diagnostic signal-to-noise ratio with therapeutic output
Macrophages in Tissue Repair, Regeneration, and Fibrosis
However, during other metabolic activities, NAD+ is consumed by NAD+-dependent enzymes and may subsequently become depleted over time, contributing to increased DNA damage, age-related illnesses and diseases, and mitochondrial malfunction
